Date published: 2026-5-3

1-800-457-3801

SCBT Portrait Logo
Seach Input

NURIM Inhibitors

NURIM inhibitors, short for Nuclear Receptor Interaction Modulators, belong to a specialized class of chemical compounds that exert their influence on nuclear receptors within the human body. Nuclear receptors are a family of proteins primarily located in the cell nucleus, which play a pivotal role in regulating gene expression. These receptors are involved in numerous physiological processes, including metabolism, cell growth, and immune response. NURIM inhibitors are designed to modulate the interactions between nuclear receptors and their target genes, thereby altering the gene expression patterns and subsequently impacting various biological pathways.

The unique feature of NURIM inhibitors is their ability to selectively target specific nuclear receptors, offering a level of precision in gene regulation that can have profound effects on cellular functions. These inhibitors typically function by binding to the nuclear receptors, either enhancing or inhibiting their activity, which, in turn, influences downstream gene expression. This class of compounds holds immense promise for scientific research and potential future applications beyond. Researchers are keenly interested in studying NURIM inhibitors to gain insights into the fundamental mechanisms of gene regulation and cellular signaling, which can lead to a deeper understanding of various diseases and potentially open up new avenues for drug development, although it's important to note that they are not drugs themselves. Additionally, the selective nature of NURIM inhibitors makes them valuable tools in elucidating the roles of specific nuclear receptors in various biological processes, further advancing our understanding of molecular biology and gene regulation.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

A tyrosine kinase inhibitor primarily targeting BCR-ABL, c-KIT, and PDGFR. It is used in the research of chronic myeloid leukemia (CML) and other cancers.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

An EGFR tyrosine kinase inhibitor. It interferes with the growth of cancer cells by inhibiting EGFR-associated tyrosine kinase activity.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

A multi-kinase inhibitor that targets RAF/MEK/ERK pathway, VEGFR, and PDGFR. It's used for renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

CDK4/6 inhibitor. It interrupts the cell cycle by blocking phosphorylation of Rb protein, thus halting progression from G1 to S phase in the cell cycle.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$117.00
$423.00
11
(1)

BRAF kinase inhibitor. It selectively inhibits mutated BRAF V600E, which is involved in cell proliferation in melanomas and other cancers.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Proteasome inhibitor. It interrupts the proteasome's ability to degrade unneeded or damaged proteins, leading to cell cycle arrest and apoptosis in cancer cells.

Olaparib

763113-22-0sc-302017
sc-302017A
sc-302017B
250 mg
500 mg
1 g
$210.00
$305.00
$495.00
10
(1)

PARP inhibitor. It interferes with the repair of DNA damage in cancer cells by blocking PARP enzyme, leading to accumulation of DNA breaks and inducing cell death.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual tyrosine kinase inhibitor targeting HER2 and EGFR. It interferes with the HER2 and EGFR pathways, inhibiting cell proliferation in HER2 and EGFR overexpressing tumors.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

JAK1/JAK2 inhibitor. It reduces inflammatory signaling by blocking the Janus-associated kinases JAK1 and JAK2, interrupting the JAK-STAT signaling pathway.

Abiraterone Acetate

154229-18-2sc-207240
5 mg
$231.00
1
(1)

CYP17 inhibitor. It blocks a crucial enzyme in testosterone synthesis, reducing androgen levels and thus inhibiting prostate cancer cell growth.